Resmed RMD
NYSE RMD
$247.84 +1.63 (+0.66%)
As of: Oct 22, 2026 · 9:45 AM EDT

Resmed (RMD) Cash from Restructuring (2020 - 2023)

Updated

Analysis

Resmed (RMD) Cash from Restructuring (2020 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 258.37 Bn 237.40 Bn 4.88 Bn
2 Abbott Laboratories 175.14 Bn 145.57 Bn 7.27 Bn
3 Danaher 166.00 Bn 149.80 Bn 3.61 Bn
4 Intuitive Surgical 152.73 Bn 132.16 Bn 1.96 Bn
5 Medtronic 119.76 Bn 85.01 Bn 6.34 Bn
6 Stryker 115.60 Bn 101.71 Bn 4.50 Bn
7 Boston Scientific 65.75 Bn 60.52 Bn 3.85 Bn
8 Becton Dickinson 54.00 Bn 51.15 Bn 2.32 Bn
9 Edwards Lifesciences 51.04 Bn 35.05 Bn 1.35 Bn
10 Resmed 35.91 Bn 29.98 Bn 861.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 9.18 Mn
Dec 31, 2020 8.67 Mn
API Access

Resmed Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=RMD&period=max&api_key=YOUR_API_KEY